| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK138712 | Ubiquitin pathway modulators for treating pancreatitis | 000 | 1 | NIH | 10/30/2024 | $0 |
| | 2025 | 2024 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK138712 | Ubiquitin pathway modulators for treating pancreatitis | 001 | 1 | NIH | 12/19/2024 | $0 |
| | 2025 | 2022 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AR081153 | Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis | 000 | 1 | NIH | 10/25/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $269,622 ) |
| | 2024 | 2024 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK138712 | Ubiquitin pathway modulators for treating pancreatitis | 000 | 1 | NIH | 9/19/2024 | $269,622 |
| | 2024 | 2022 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AR081153 | Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis | 000 | 1 | NIH | 10/16/2023 | $0 |
| | 2024 | 2022 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43HL162163 | Parkin activators for cardioprotective therapies | 000 | 1 | NIH | 7/9/2024 | $0 |
| | 2024 | 2021 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK127851 | Novel TXNIP degraders for treating diabetes | 000 | 1 | NIH | 2/26/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | PROGENRA INC | 271A GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM139493 | Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs) | 000 | 1 | NIH | 5/1/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $551,493 ) |
| | 2022 | 2022 | PROGENRA INC. | 271A GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43HL162163 | Parkin activators for cardioprotective therapies | 000 | 1 | NIH | 3/30/2022 | $296,932 |
| | 2022 | 2022 | PROGENRA INC. | 271A GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AR081153 | Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis | 000 | 1 | NIH | 9/1/2022 | $254,561 |
| | 2022 | 2019 | PROGENRA INC. | 271A GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK120250 | Nonalcoholic Steatohepatitis Therapies from the Ubiquitin Pathway | 000 | 1 | NIH | 2/16/2022 | $0 |
| | 2022 | 2019 | PROGENRA INC. | 271A GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AR074799 | Ubiquitin E3 ligase activators for treatment of psoriasis | 000 | 1 | NIH | 4/6/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $265,978 ) |
| | 2021 | 2021 | PROGENRA INC. | 271A GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK127851 | Novel TXNIP degraders for treating diabetes | 000 | 1 | NIH | 9/5/2021 | $265,978 |
| | 2021 | 2018 | PROGENRA INC. | 271A GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG053092 | Small molecule Parkin activators to treat Alzheimer's Disease | 000 | 3 | NIH | 1/30/2021 | $0 |
| | 2021 | 2018 | PROGENRA INC. | 271A GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AI138753 | Small-molecule inhibition of mechanisms shared across pathogenic cells in systemic lupus erythematosus | 000 | 1 | NIH | 11/16/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $297,442 ) |
| | 2020 | 2020 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM139493 | Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs) | 000 | 1 | NIH | 7/9/2020 | $297,442 |
| | 2020 | 2018 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AI109980 | Ubiquitin pathway inhibitors for treatment of asthma | 000 | 3 | NIH | 6/8/2020 | $0 |
| | 2020 | 2017 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43CA213582 | Small molecule ubiquitin ligase modulators for immunotherapy of cancer | 000 | 1 | NIH | 3/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $449,079 ) |
| | 2019 | 2019 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK120250 | Nonalcoholic Steatohepatitis Therapies from the Ubiquitin Pathway | 000 | 1 | NIH | 9/10/2019 | $224,618 |
| | 2019 | 2019 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AR074799 | Ubiquitin E3 ligase activators for treatment of psoriasis | 000 | 1 | NIH | 8/30/2019 | $224,461 |
| | 2019 | 2018 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG053092 | Small molecule Parkin activators to treat Alzheimer's Disease | 000 | 3 | NIH | 6/3/2019 | $0 |
| | 2019 | 2017 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44CA174037 | Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment | 000 | 3 | NIH | 7/8/2019 | $0 |
| | 2019 | 2016 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R41HL130207 | In vitro human model for individualized response to CFTR modulators | 000 | 1 | NIH | 1/10/2019 | $0 |
| | 2019 | 2016 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43HL134411 | A novel mechanism based therapy for cystic fibrosis | 000 | 1 | NIH | 1/10/2019 | $0 |
| | 2019 | 2016 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AI126950 | Novel ubiquitin protease inhibitor for treating asthma | 000 | 1 | NIH | 11/1/2018 | $0 |
| | 2019 | 2016 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG053092 | Small molecule Parkin activators to treat Alzheimer's Disease | 000 | 1 | NIH | 10/25/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,502,565 ) |
| | 2018 | 2018 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG053092 | Small molecule Parkin activators to treat Alzheimer's Disease | 000 | 3 | NIH | 5/18/2018 | $643,048 |
| | 2018 | 2018 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AI109980 | Ubiquitin pathway inhibitors for treatment of asthma | 000 | 3 | NIH | 12/22/2017 | $636,155 |
| | 2018 | 2018 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AI138753 | Small-molecule inhibition of mechanisms shared across pathogenic cells in systemic lupus erythematosus | 000 | 1 | NIH | 4/27/2018 | $223,362 |
| | 2018 | 2015 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44HL114299 | Novel molecular therapeutics for cystic fibrosis | 000 | 3 | NIH | 10/20/2017 | $0 |
| | 2018 | 2015 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG049535 | Novel E3 ligase inhibitors for treatment of neurodegenerative disease | 000 | 1 | NIH | 12/12/2017 | $0 |
| | 2018 | 2015 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG052242 | Mitophagy inhibitors for treatment of Alzheimer's Disease | 000 | 1 | NIH | 12/12/2017 | $0 |
| | 2018 | 2015 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44GM097827 | Ubiquitin E3 ligase detection by fluorescence resonance transfer | 000 | 3 | NIH | 10/19/2017 | $0 |
| | 2018 | 2015 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44ES025600 | Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol | 000 | 3 | NIH | 12/5/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,447,866 ) (Continued on the next page) |
| | 2017 | 2017 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG053092 | Small molecule Parkin activators to treat Alzheimer's Disease | 000 | 2 | NIH | 8/25/2017 | $741,032 |
| | 2017 | 2017 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43CA213582 | Small molecule ubiquitin ligase modulators for immunotherapy of cancer | 000 | 1 | NIH | 8/29/2017 | $224,995 |
| | 2017 | 2017 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44CA174037 | Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment | 000 | 3 | NIH | 1/26/2017 | $748,944 |
| | 2017 | 2017 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AI109980 | Ubiquitin pathway inhibitors for treatment of asthma | 000 | 2 | NIH | 1/10/2017 | $757,044 |
| | 2017 | 2015 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43DK104482 | Development of novel drugs to treat obesity | 000 | 1 | NIH | 8/7/2017 | $0 |
| | 2017 | 2014 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43NS087686 | Novel treatment for Huntington???s Disease | 001 | 1 | NIH | 9/1/2017 | $199,278 |
| | 2017 | 2014 | PROGENRA, INC | 277 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43CA180173 | Ubiquitin based therapy of aggressive cancer cell populations | 000 | 1 | NIH | 11/23/2016 | $0 |
|
